Equities

Biodexa Pharmaceuticals PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BDRX:NAQ

Biodexa Pharmaceuticals PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.41
  • Today's Change0.33 / 30.56%
  • Shares traded442.01k
  • 1 Year change-96.70%
  • Beta1.0365
Data delayed at least 15 minutes, as of Feb 17 2026 18:18 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.

  • Revenue in USD (TTM)0.00
  • Net income in USD-8.48m
  • Incorporated2014
  • Employees13.00
  • Location
    Biodexa Pharmaceuticals PLC1 Caspian Point, Caspian WayABINGDON CF10 4DQUnited KingdomGBR
  • Phone+44 123 584 1575
  • Websitehttps://www.biodexapharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Windtree Therapeutics Inc0.00-48.83m394.39k14.00---------8.38-8.380.00-0.34490.00----0.00-172.27-48.72-791.65-52.57------------22.36------72.96---42.51--
Avenue Therapeutics Inc1.40m-3.74m477.51k2.00--0.1343--0.3401-1.55-1.550.501.120.4422----702,000.00-119.06-159.81-122.59-215.40-----269.23------0.00-------12.29------
Regenerative Medical Technology Grop Inc5.04m-7.06m512.42k1.00------0.1017-0.5629-0.56290.4019-2.401.3024.9569.50---182.18-177.25----59.7664.83-140.06-465.060.0784-0.0279----70.44167.3043.31------
Bio Path Holdings Inc0.00-11.18m536.04k10.00---------1.71-1.710.00-0.8660.00----0.00-611.66-81.00---90.58-----------65.76--------38.46------
Longevity Health Holdings Inc1.46m-5.74m545.07k15.00------0.374-5.22-5.221.26-2.230.50771.1147.3197,153.34-199.84------57.86---393.63--0.2676----------36.91------
Novelstem International Corp3.00k2.31m562.58k15.000.2495----187.530.04810.04810.00006-0.04380.0281--0.80--630.69----------22,424.33----------0.00--22.79------
Helix BioMedix Inc2.07m-2.58m609.46k8.00--0.3887--0.295-15.60-15.6012.486.950.80471.874.55258,238.80-100.64-146.31-120.73-173.5768.9630.80-125.06-527.121.69-14.570.00--122.0792.8067.73---29.08--
Biodexa Pharmaceuticals PLC-ADR0.00-8.48m667.96k13.00--0.0043-----703.05-703.050.00251.510.00----0.00-43.26-78.06-54.55-109.39-------2,404.45----0.042---100.00--19.07--19.40--
PMGC Holdings Inc285.95k-4.48m696.95k2.00--0.03--2.44-57.57-129.013.9345.640.02190.3731.98142,975.00-34.29---48.32--27.29---1,567.42--1.77-32.160.2734-------142.45------
Hepion Pharmaceuticals Inc0.00-9.17m697.22k22.00--0.4279-----13.39-13.390.000.28610.00-------245.96-65.13-417.51-73.82-----------5.250.0606------73.04------
CeCors Inc-100.00bn-100.00bn763.78k6.00---------------0.0163------------------------------------22.70------
Protagenic Therapeutics Inc-100.00bn-100.00bn773.95k1.00---------------2.43------------------------0.2945------------------
CERo Therapeutics Holdings Inc0.00-49.19m835.39k8.00---------175.56-175.560.00-3.040.00----0.00-282.75---------------------------52.12------
Lipella Pharmaceuticals Inc389.79k-5.33m887.20k5.00--0.5964--2.28-2.41-2.410.12860.32190.1729--25.0877,958.00-236.36-101.93-336.65-125.09-----1,367.34-592.18----0.00--19.29-5.04-8.60------
Data as of Feb 17 2026. Currency figures normalised to Biodexa Pharmaceuticals PLC's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.